These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 11386927)

  • 1. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
    Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
    JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
    Toto RD
    Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
    Lea J; Greene T; Hebert L; Lipkowitz M; Massry S; Middleton J; Rostand SG; Miller E; Smith W; Bakris GL
    Arch Intern Med; 2005 Apr; 165(8):947-53. PubMed ID: 15851648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure control, drug therapy, and kidney disease.
    Contreras G; Greene T; Agodoa LY; Cheek D; Junco G; Dowie D; Lash J; Lipkowitz M; Miller ER; Ojo A; Sika M; Wilkening B; Toto RD;
    Hypertension; 2005 Jul; 46(1):44-50. PubMed ID: 15897360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
    Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
    Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
    Douglas JG; Agodoa L
    Kidney Int Suppl; 2003 Feb; (83):S74-6. PubMed ID: 12864879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.
    Flack JM
    Curr Hypertens Rep; 2002 Jun; 4(3):183-4. PubMed ID: 12003698
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
    Thornley-Brown D; Wang X; Wright JT; Randall OS; Miller ER; Lash JP; Gassman J; Contreras G; Appel LJ; Agodoa LY; Cheek D
    Arch Intern Med; 2006 Apr; 166(7):797-805. PubMed ID: 16606818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
    Vidt DG
    Curr Hypertens Rep; 2001 Oct; 3(5):379-80. PubMed ID: 11551370
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive drugs and renal protection.
    Fukuda M; Usami T; Yoshida A; Kimura G
    JAMA; 2003 Mar; 289(9):1102-3; author reply 1103. PubMed ID: 12622571
    [No Abstract]   [Full Text] [Related]  

  • 16. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
    Sica DA
    J Clin Hypertens (Greenwich); 2003; 5(2):159-67. PubMed ID: 12671332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.
    Knoll GA; Fergusson D; Chassé M; Hebert P; Wells G; Tibbles LA; Treleaven D; Holland D; White C; Muirhead N; Cantarovich M; Paquet M; Kiberd B; Gourishankar S; Shapiro J; Prasad R; Cole E; Pilmore H; Cronin V; Hogan D; Ramsay T; Gill J
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):318-26. PubMed ID: 26608067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.